Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR039 in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT04693676Phase 1Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2020
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of prizloncabtagene autoleucel in B-cell non-Hodgkin lymphoma, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Maximum Tolerated Dose up to 24 months, Dose Limiting Toxicity up to 28 days and 1 more. Status: unknown.
02
Drugs
prizloncabtagene autoleucel
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04693676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04693676.